Retatrutide

Retaglutide is a new dipeptidyl peptidase-4 (DPP-4) inhibitor class hypoglycemic drug that can prevent the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin-releasing polypeptide (GIP) by DPP-4 enzyme in the intestine and blood, prolonging their activity, thereby promoting insulin secretion by pancreatic β cells without affecting the basal level of fasting insulin, while reducing the secretion of glucagon by pancreatic α cells, thereby more effectively controlling postprandial blood sugar. It performs well in terms of hypoglycemic effect, tolerance, and compliance.